Target intelligence / Profile preview

Ubiquitin specific peptidase 3 (USP3)

Target
USP3
Molecular classification
Enzyme, Deubiquitinating enzyme (DUB), Ubiquitin-specific protease family
01

Overview

Ubiquitin specific peptidase 3 (USP3) is a deubiquitinating enzyme belonging to the ubiquitin-specific protease family. It functions by removing ubiquitin molecules from specific protein substrates, thereby preventing their proteasomal degradation and maintaining protein homeostasis[5]. USP3 is involved in several key biological processes, including regulation of the cell cycle, DNA damage repair (notably by deubiquitinating histone H2A and γH2AX at DNA damage sites), and innate immune signaling through stabilization of adapter proteins like ASC during inflammasome assembly[1][4][5]. Overexpression or dysregulation of USP3 has been implicated in the progression of various cancers, where it can promote proliferation, migration, and invasion of tumor cells—partly via stabilization of effectors such as EPHA2 and activation of the PI3K/AKT pathway[2]. USP3 is also involved in antiviral defense, such as inhibiting HIV-1 by stabilizing A3G, an intrinsic antiviral factor[3]. As a result, USP3 is being explored as a potential therapeutic target in oncology, immunology, and infectious diseases, though specific pharmacological inhibitors are not yet clinically available[5].

Other names
Ubiquitin carboxyl-terminal hydrolase 3Deubiquitinating enzyme 3Ubiquitin thioesterase 3Ubiquitin-specific-processing protease 3SIH003UBPUSP3
02

Mechanism of action

Inhibition of USP3 leads to increased ubiquitination and degradation of specific substrate proteins, affecting cell cycle progression, DNA repair, and immune signaling[2][5] Modulation of USP3 can alter inflammatory responses and cellular tolerance via targets such as ASC[1][5]

03

Biological functions

Deubiquitination of protein substratesRegulation of cell cycleDNA damage repairModulation of innate immune responses, including inflammasome activationRegulation of protein stability
04

Disease associations

Cancer (including osteosarcoma, gastric, lung, colorectal cancers)InflammationImmune response disordersViral infection (notably HIV-1)
05

Safety considerations

Potential for impaired DNA repair (when inhibited)Aberrant immune activation or suppressionEffects on normal cell cycle and proliferation when targeting USP3 in cancer
06

Interacting drugs

Digoxin (implicated in pathways affecting USP3)

1 more in the full profile.

07

Biomarkers

USP3 expression levels (cancer prognosis, immune cell profiling)EPHA2 stability (in cancer models)

Beyond the preview

Go deeper on Ubiquitin specific peptidase 3 (USP3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ubiquitin specific peptidase 3 (USP3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call